Joel Greenblatt’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-78,750
| Closed | -$3.17M | – | 1800 |
|
|
2026
Q1 | $3.17M | Sell |
78,750
-89,705
| -53% | -$1.93M | 0.01% | 983 |
|
|
2025
Q4 | $4.23M | Buy |
168,455
+41,297
| +32% | +$969K | 0.02% | 851 |
|
|
2025
Q3 | $2.88M | Buy |
127,158
+7,929
| +7% | +$185K | 0.01% | 909 |
|
|
2025
Q2 | $2.06M | Buy |
119,229
+84,944
| +248% | +$1.57M | 0.01% | 922 |
|
|
2025
Q1 | $750K | Buy |
34,285
+9,986
| +41% | +$276K | 0.01% | 1092 |
|
|
2024
Q4 | $775K | Buy |
+24,299
| New | +$731K | 0.01% | 991 |
|
|
2024
Q2 | – | Sell |
-3,513
| Closed | -$206K | – | 1415 |
|
|
2024
Q1 | $206K | Hold |
3,513
| – | – | ﹤0.01% | 1285 |
|
|
2023
Q4 | $210K | Buy |
+3,513
| New | +$178K | ﹤0.01% | 1236 |
|
|
2023
Q3 | – | Sell |
-2,720
| Closed | -$248K | – | 1319 |
|
|
2023
Q2 | $248K | Sell |
2,720
-1,132
| -29% | -$97.7K | 0.01% | 1176 |
|
|
2023
Q1 | $254K | Buy |
+3,852
| New | +$222K | 0.01% | 1184 |
|
|
2022
Q4 | – | Sell |
-4,458
| Closed | -$304K | – | 1207 |
|
|
2022
Q3 | $304K | Buy |
+4,458
| New | +$264K | 0.01% | 973 |
|
Other funds holding APLS
Joel Greenblatt's APLS Position: Q2 2026 in Review
Joel Greenblatt sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 78,750 shares — an estimated $3.17M sold.
Joel Greenblatt first reported a position in APLS in Q3 2022 and held it in 11 quarters. The position peaked at $4.23M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Joel Greenblatt reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Joel Greenblatt sold 78,750 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.17M.
- Joel Greenblatt first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 11 quarters.
- Joel Greenblatt's Apellis Pharmaceuticals position peaked at $4.23M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.